Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk

Archives of General Psychiatry

Volumn 69, Issue 3, 2012, Pages 220-229

  Fusar Poli, Paolo ^a,b   Bonoldi, Ilaria ^a,b   Yung, Alison R ^c   Borgwardt, Stefan ^a,d   Kempton, Matthew J ^a   Valmaggia, Lucia ^a   Barale, Francesco ^b   Caverzasi, Edgardo ^b   McGuire, Philip ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DEMOGRAPHY; DIAGNOSTIC TEST; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MEDICAL LITERATURE; METHODOLOGY; OUTCOME ASSESSMENT; PSYCHIATRIC TREATMENT; PSYCHOMETRY; PSYCHOSIS; PUBLICATION; PUBLISHING; SENSITIVITY ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; YOUNG ADULT;

EID: 84857862940     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.1472     Document Type: Article

References (95)

1. Howes OD, Lim SJ, Fusar-Poli P. Mind the translation gap: problems in the implementation of early intervention services. Psychol Med. 2010;40(1):171-172.
2. Sullivan HS. The onset of schizophrenia: 1927. Am J Psychiatry. 1994;151(6) (suppl):134-139.
3. McGorry PD, Nelson B, Amminger GP, Bechdolf A, Francey SM, Berger G, Riecher-Rössler A, Klosterkötter J, Ruhrmann S, Schultze-Lutter F, Nordentoft M, Hickie I, McGuire P, Berk M, Chen EY, Keshavan MS, Yung AR. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry. 2009;70(9):1206-1212.
4. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull. 1996;22(2):283-303. (Pubitemid 26174575)
5. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004; 67(2-3):131-142. (Pubitemid 38251443)
6. Cornblatt BA, Lencz T, Smith CW, Olsen R, Auther AM, Nakayama E, Lesser ML, Tai JY, Shah MR, Foley CA, Kane JM, Correll CU. Can antidepressants be used to treat the schizophrenia prodrome? results of a prospective, naturalistic treatment study of adolescents. J Clin Psychiatry. 2007;68(4):546-557. (Pubitemid 46663037)
7. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, Phillips LJ, Bechdolf A, Buckby J, McGorry PD. Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res. 2008;105(1-3):10-17.
8. Schultze-Lutter F. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull. 2009;35(1):5-8.
9. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry. 2001;58(2):158- 164.
10. Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz R, McGuire P, Borgwardt S. Cognitive functioning in prodromal psychosis: a metaanalysis. Arch Gen Psych. In press.
11. Koutsouleris N, Schmitt GJ, Gaser C, Bottlender R, Scheuerecker J, McGuire P, Burgermeister B, Born C, Reiser M, Möller HJ, Meisenzahl EM. Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. Br J Psychiatry. 2009;195(3):218-226.
12. Jacobson S, Kelleher I, Harley M, Murtagh A, Clarke M, Blanchard M, Connolly C, O'Hanlon E, Garavan H, Cannon M. Structural and functional brain correlates of subclinical psychotic symptoms in 11-13 year old schoolchildren. Neuroimage. 2010;49(2):1875-1885.
13. Meisenzahl EM, Koutsouleris N, Gaser C, Bottlender R, Schmitt GJ, McGuire P, Decker P, Burgermeister B, Born C, Reiser M, Möller HJ. Structural brain alterations in subjects at high-risk of psychosis: a voxel-based morphometric study. Schizophr Res. 2008;102(1-3):150-162.
14. Fusar-Poli P, Borgwardt S, Crescini A, D'Este G, Kempton M, Lawrie S, Guire PM, Sacchetti E. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis [published online ahead of print December 17, 2010]. Neurosci Biobehav Rev. 2011;35(5):1175-1185. doi:10.1016/j.neubiorev.2010.12.005.
15. Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical maps of psychois onset: voxel-wise meta-analysis of antipschotic-naïve VBM studies [published online ahead of print November 17, 2011]. Schizophr Bull. 2011. doi: 10 .1093/schbul/sbr134.
16. Seiferth NY, Pauly K, Habel U, Kellermann T, Shah NJ, Ruhrmann S, Klosterkötter J, Schneider F, Kircher T. Increased neural response related to neutral faces in individuals at risk for psychosis. Neuroimage. 2008;40(1):289-297.
17. Brüne M, Ozgürdal S, Ansorge N, von Reventlow HG, Peters S, Nicolas V, Tegenthoff M, Juckel G, Lissek S. An fMRI study of "theory of mind" in at-risk states of psychosis: comparison with manifest schizophrenia and healthy controls. Neuroimage. 2011;55(1):329-337.
18. Morey RA, Inan S, Mitchell TV, Perkins DO, Lieberman JA, Belger A. Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing. Arch Gen Psychiatry. 2005;62(3):254-262. (Pubitemid 40990970)
19. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher-Rössler A, Borgwardt SJ. Neuroimaging predictors of transition to psychosis - a systematic review and meta-analysis. Neurosci Biobehav Rev. 2010;34(8):1207-1222.
20. Fusar-Poli P, Perez J, Broome M, Borgwardt S, Placentino A, Caverzasi E, Cortesi M, Veggiotti P, Politi P, Barale F, McGuire P. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2007;31(4):465-484. (Pubitemid 46527879)
21. Crossley NA, Mechelli A, Fusar-Poli P, Broome MR, Matthiasson P, Johns LC, Bramon E, Valmaggia L, Williams SC, McGuire PK. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp. 2009;30(12):4129-4137.
22. Fusar-Poli P, Howes OD, Allen P, BroomeM, Valli I, Asselin MC, Grasby PM,McGuire PK. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry. 2010;67(7):683-691.
23. Fusar-Poli P, Stone JM, Broome MR, Valli I, Mechelli A, McLean MA, Lythgoe DJ, O'Gorman RL, Barker GJ, McGuire PK. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry. 2011;(9):881-890 68.
24. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, II: meta-analysis of 18F/11C DOPA PET studies. Schizophr Bull. In press.
25. Ruhrmann S, Schultze-Lutter F, Bechdolf A, Klosterkötter J. Intervention in atrisk states for developing psychosis. Eur Arch Psychiatry Clin Neurosci. 2010; 260(suppl 2):S90-S94.
26. Fusar-Poli P, Yung A. Should attenuated psychosis syndrome be included in the DSM5? the debate. Lancet. 2011 http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Retrieve&db=PubMed&list-uids=18037073&dopt=Abstract. In press.
27. Carpenter WT, van Os J. Should attenuated psychosis syndrome be a DSM-5 diagnosis? Am J Psychiatry. 2011;168(5):460-463.
28. Nelson B, Yung AR. Should a risk syndrome for first episode psychosis be included in the DSM-5? Curr Opin Psychiatry. 2011;24(2):128-133.
29. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill - advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res. 2010;120(1-3):23-37.
30. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28-37.
31. Yung AR, Yuen HP, Berger G, Francey S, Hung TC, Nelson B, Phillips L, McGorry P. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull. 2007;33(3):673-681. (Pubitemid 47343718)
32. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: review of studies. Acta Psychiatr Scand. 2006;113(4):247-272.
33. Olsen KA, Rosenbaum B. Prospective investigations of the prodromal state of schizophrenia: assessment instruments. Acta Psychiatr Scand. 2006;113(4): 273-282.
34. Fusar-Poli P, Borgwardt S, Valmaggia L. Heterogeneity in the assessment of the at-risk mental state for psychosis. Psychiatr Serv. 2008;59(7):813.
35. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW. Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2003;29(4):703-715. (Pubitemid 38181951)
36. Yung AR, Yuen HP, McGorry PD, Phillips LJ, Kelly D, Dell'Olio M, Francey SM, Cosgrave EM, Killackey E, Stanford C, Godfrey K, Buckby J. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005;39(11-12):964-971. (Pubitemid 43904432)
37. Hodges A, Byrne M, Grant E, Johnstone E. People at risk of schizophrenia: sample characteristics of the first 100 cases in the Edinburgh High-Risk Study. Br J Psychiatry. 1999;174:547-553. (Pubitemid 29278690)
38. Johnstone EC, Abukmeil SS, Byrne M, Clafferty R, Grant E, Hodges A, Lawrie SM, Owens DG. Edinburgh High Risk Study - findings after four years: demographic, attainment and psychopathological issues. Schizophr Res. 2000;46(1):1-15.
39. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry. 2004;161(3):398-413. (Pubitemid 38326093)
40. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535doi:10.1136/bmj.b2535.
41. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282(11):1054-1060. (Pubitemid 29436453)
42. Paulson JF, Bazemore SD. Prenatal and postpartum depression in fathers and its association with maternal depression: a meta-analysis. JAMA. 2010;303 (19):1961-1969.
43. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB; Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008-2012. (Pubitemid 30214957)
44. Borenstein MHL, Higgins J, Rothstein H. Comprehensive Meta-analysis, Version 2. Englewood, NJ: Biostat, Inc; 2005.
45. Nielssen O, Large M. Rates of homicide during the first episode of psychosis and after treatment: a systematic review and meta-analysis. Schizophr Bull. 2010; 36(4):702-712.
46. Gimp, the GNU image manipulation program. 2008. http://www.gimp.org/.
47. Ruhrmann S, Schultze-Lutter F, Salokangas RK, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow HG, Klosterkötter J. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis Study. Arch Gen Psychiatry. 2010;67(3):241-251.
48. Lipsey M, Wilson D. Practical Meta-analysis. Thousand Oaks, CA: Sage Publications; 2000.
49. Cooper H, Hedges L, Valentine J. Handbook of Research Synthesis and Meta-analysis. New York, NY: Russell Sage Foundation; 2009.
50. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634. (Pubitemid 27387172)
51. Orwin R. A fail-safe N for effect size in meta-analysis. J Stat Educ. 1983;8(2):157- 159.
52. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1):19-28. (Pubitemid 46041735)
53. Yung AR, Phillips LJ, McGorry PD, McFarlane CA, Francey S, Harrigan S, Patton GC, Jackson HJ. Prediction of psychosis: a step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl. 1998;172(33):14-20. (Pubitemid 28258893)
54. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with "at-risk mental states."Schizophr Res. 2004;71(2-3):227-237. (Pubitemid 39330501)
55. Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, Cornblatt BA. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry. 2006;59(9):863-871.
56. Schultze-Lutter F, Klosterkötter J, Picker H, Steinmeyer E, Ruhrmann S. Predicting first-episode psychosis by basic symptoms criteria. Clin Neuropsychiatry. 2007;4(1):11-22. (Pubitemid 47072411)
57. Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, Francey SM, Yung AR. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res. 2007; 96(1-3):25-33. (Pubitemid 47494628)
58. Morrison AP, French P, Parker S, Roberts M, Stevens H, Bentall RP, Lewis SW. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr Bull. 2007;33 (3):682-687. (Pubitemid 47343709)
59. Riecher-Rössler A, Pflueger MO, Aston J, Borgwardt SJ, Brewer WJ, Gschwandtner U, Stieglitz RD. Efficacy of using cognitive status in predicting psychosis: a 7-year follow-up. Biol Psychiatry. 2009;66(11):1023-1030.
60. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophr Bull. 2009;35(5):894-908.
61. Kéri S, Kiss I, Kelemen O. Effects of a neuregulin 1 variant on conversion to schizophrenia and schizophreniform disorder in people at high risk for psychosis. Mol Psychiatry. 2009;14(2):118-119.
62. Lemos-Giráldez S, Vallina-Fernández O, Fernández- Iglesias P, Vallejo-Seco G, Fonseca-Pedrero E, Pai'no-Piñeiro M, Sierra-Baigrie S, Garci'a-Pelayo P, Pedrejón- Molino C, Alonso-Bada S, Gutiérrez-Pérez A, Ortega-Ferrández JA. Symptomatic and functional outcome in youth at ultra-high risk for psychosis: a longitudinal study. Schizophr Res. 2009;115(2-3):121-129.
63. Nelson B, Yung AR. Can clinicians predict psychosis in an ultra high risk group? Aust N Z J Psychiatry. 2010;44(7):625-630.
64. Bechdolf A, Thompson A, Nelson B, Cotton S, Simmons MB, Amminger GP, Leicester S, Francey SM, McNab C, Krstev H, Sidis A, McGorry PD, Yung AR. Experience of trauma and conversion to psychosis in an ultra-high-risk (prodromal) group. Acta Psychiatr Scand. 2010;121(5):377-384.
65. Demjaha A, Valmaggia L, Stahl D, Byrne M, McGuire P. Disorganization/ cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis [published online ahead of print August 12, 2010]. Schizophr Bull. 2010;(Sep):2. doi:10.1093/schbul/sbq088.
66. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for psychosis. Schizophr Res. 2010;116(2-3):168-172.
67. Sabb FW, van Erp TG, Hardt ME, Dapretto M, Caplan R, Cannon TD, Bearden CE. Language network dysfunction as a predictor of outcome in youth at clinical high risk for psychosis. Schizophr Res. 2010;116(2-3):173-183.
68. Velthorst E, Nieman DH, Klaassen RM, Becker HE, Dingemans PM, Linszen DH, De Haan L. Three-year course of clinical symptomatology in young people at ultra high risk for transition to psychosis. Acta Psychiatr Scand. 2011;123(1):36-42.
69. Mittal VA, Walker EF, Bearden CE, Walder D, Trottman H, Daley M, Simone A, Cannon TD. Markers of basal ganglia dysfunction and conversion to psychosis: neurocognitive deficits and dyskinesias in the prodromal period. Biol Psychiatry. 2010;68(1):93-99.
70. Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146-154.
71. Ziermans TB, Schothorst PF, Sprong M, van Engeland H. Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res. 2011;126 (1-3):58-64.
72. Riecher-Rössler A, Aston J, Ventura J, Merlo M, Borgwardt S, Gschwandtner U, Stieglitz RD. The Basel Screening Instrument for Psychosis (BSIP): development, structure, reliability and validity. Fortschr Neurol Psychiatr. 2008;76 (4):207-216. (Pubitemid 351985311)
73. Cannon TD, Cornblatt B, McGorry P. The empirical status of the ultra high-risk (prodromal) research paradigm. Schizophr Bull. 2007;33(3):661-664. (Pubitemid 47343732)
74. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558. (Pubitemid 34746062)
75. Yung AR, Phillips LJ, Yuen HP, Francey SM,McFarlane CA, Hallgren M, McGorry PD. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32. (Pubitemid 36015785)
76. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002;59(10):921-928.
77. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006;163 (5):790-799. (Pubitemid 44464525)
78. Schultze-Lutter F, Ruhrmann S, Berning J, Maier W, Klosterkötter J. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull. 2010;36(1):182-191.
79. Thompson A, Nelson B, Yung A. Predictive validity of clinical variables in the "at risk" for psychosis population: international comparison with results from the North American Prodrome Longitudinal Study [published online ahead of print October 29, 2010]. Schizophr Res. 2011;126(1-3):51-57.
80. Nelson B, Yuen K, Yung AR. Ultra high risk (UHR) for psychosis criteria: are there different levels of risk for transition to psychosis? Schizophr Res. 2011;125 (1):62-68.
81. Koutsouleris N, Davatzikos C, Bottlender R, Patschurek-Kliche K, Scheuerecker J, Decker P, Gaser C, Möller HJ, Meisenzahl EM. Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification [published online ahead of print May 16, 2011]. Schizophr Bull. 2011;(May):16. doi:10.1093/schbul/sbr037.
82. Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, Spiering M, Schmitz N, Linszen DH. Symptomatology and neuropsychological functioning in cannabis-using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z J Psychiatry. 2010;44(3):230-236.
83. Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet. 2007;370(9601):1746-1748. (Pubitemid 350137483)
84. Carpenter WT Jr. Criticism of the DSM-V risk syndrome: a rebuttal. Cogn Neuropsychiatry. 2011;16(2):101-106.
85. Fusar-Poli P, Byrne M, Valmaggia L, Day F, Tabraham P, Johns L, McGuire P; OASIS Team. Social dysfunction predicts two years clinical outcomes in people at ultrahigh risk for psychosis. J Psychiatr Res. 2010;44(5):294-301.
86. McGlashan TH, Addington J, Cannon T, Heinimaa M, McGorry P, O'Brien M, Penn D, Perkins D, Salokangas RK, Walsh B, Woods SW, Yung A. Recruitment and treatment practices for help-seeking "prodromal" patients. Schizophr Bull. 2007; 33(3):715-726. (Pubitemid 47343726)
87. Yung AR, Nelson B, Thompson AD, Wood SJ. Should a "risk syndrome for psychosis"be included in the DSM-V? Schizophr Res. 2010;120(1-3):7-15.
88. Corcoran CM, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res. 2010; 120(1-3):16-22.
89. Drake RJ, Lewis SW. Valuing prodromal psychosis: what do we get and what is the price? Schizophr Res. 2010;120(1-3):38-41.
90. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry. 2011;68(2):128-137.
91. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry Suppl. 2005;48:s120- s124.
92. Schimmelmann BG, Michel C, Schaffner N, Schultze-Lutter F. What percentage of people in the general population satisfies the current clinical at-risk criteria of psychosis? Schizophr Res. 2011;125(1):99-100.
93. Van Os J, Linscott R, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis proneness-persistence-impairment model of psychotic disorder. Psychol Med. 2009;39(2):179-195.
94. Green CE, McGuire PK, Ashworth M, Valmaggia LR; Outreach and Support in South London (OASIS). Outcomes of non-attenders to a service for people at high risk of psychosis: the case for a more assertive approach to assessment. Psychol Med. 2011;41(2):243-250.
95. Fusar-Poli P, Borgwardt S. Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis. Med Hypotheses. 2007;69 (4):959-960. (Pubitemid 47248099)